Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ana Oaknin, Kalyan Banda, Charles Drescher, Vincent Ribrag, Hedy L. Kindler, Harriet S. Walter, Alok Tewari, Elvire Pons-Tostivint, Nehal J. Lakhani, R. Donald Harvey, Ryan J. Sullivan, Pier Luigi Zinzani, Antonio Gonzalez Martin, Lauriane Eberst, Luis Manso Sánchez, Anjali Thakur, Lennart Kann, Archana Reddy, Nicola Faulhaber, Linda Duska
Institutions: Vall d'Hebron Institute of Oncology, Fred Hutch Cancer Center, Institut Gustave Roussy, University of Chicago Medical Center, University Hospitals of Leicester NHS Trust, Dana-Farber Cancer Institute, Centre Hospitalier Universitaire de Nantes, Winship Cancer Institute, Massachusetts General Hospital, University of Bologna, Clinica Universidad de Navarra, Hospital Universitario 12 De Octubre, MorphoSys (Germany), University of Virginia Health System
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: MorphoSys
OpenAlex ID: W4399667120